Document Detail


Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis.
MedLine Citation:
PMID:  20804515     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Matrix Gla protein (MGP) is a calcification inhibitor and alterations in circulating MGP have been observed in different populations characterized by vascular calcification. We hypothesized that patients with calcific valvular aortic stenosis (AS) would have dysregulated circulating MGP levels. DESIGN AND SUBJECTS: We examined plasma levels of nonphosphorylated carboxylated and undercarboxylated MGP (dp-cMGP and dp-ucMGP, respectively) in 147 patients with symptomatic severe AS and in matched healthy controls. MAIN OUTCOME MEASURES: We further investigated the relationship between MGP levels and aortic pressure gradients and valve area by echocardiography and measures of heart failure. Finally, we assessed the prognostic value of elevated plasma dp-ucMGP level in relation to all-cause mortality in patients with AS. RESULTS: We found markedly enhanced plasma levels of dp-cMGP and in particular of dp-ucMGP in patients with symptomatic AS. Although only weak correlations were found with the degree of AS, circulating dp-ucMGP was associated with cardiac function and long-term mortality in multivariate analysis. CONCLUSIONS: A dysregulated MGP system may have a role in the development of left ventricular dysfunction in patients with symptomatic AS.
Authors:
T Ueland; L Gullestad; C P Dahl; P Aukrust; S Aakhus; O G Solberg; C Vermeer; L J Schurgers
Related Documents :
16820605 - Outcomes of medical management of acute type b aortic dissection.
8519705 - The aortic width as an index of hypertension--how specific?
17258095 - Aortic root translocation plus arterial switch for transposition of the great arteries ...
2722285 - Restenosis is a common feature of the angiographic follow-up after balloon valvoplasty ...
11039715 - Rapidly growing primary cardiac leiomyosarcoma: report of a case.
10311835 - The artificial heart. costs, risks, and benefits--an update.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of internal medicine     Volume:  268     ISSN:  1365-2796     ISO Abbreviation:  J. Intern. Med.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-22     Completed Date:  2010-11-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8904841     Medline TA:  J Intern Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  483-92     Citation Subset:  IM    
Copyright Information:
© 2010 The Association for the Publication of the Journal of Internal Medicine.
Affiliation:
Research Institute for Internal Medicine, Rikshospitalet University Hospital, University of Oslo, Oslo, Norway. thor.ueland@medisin.uio.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Anticoagulants / therapeutic use
Aorta / pathology,  ultrasonography
Aortic Valve / pathology,  ultrasonography
Aortic Valve Stenosis / blood*,  drug therapy,  mortality*
Biological Markers / blood
Blood Pressure / physiology
Calcinosis / blood,  mortality
Calcium-Binding Proteins / blood,  metabolism*
Cause of Death
Echocardiography
Extracellular Matrix Proteins / blood*
Female
Heart Failure / blood*
Humans
Male
Middle Aged
Prognosis
Warfarin / therapeutic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Biological Markers; 0/Calcium-Binding Proteins; 0/Extracellular Matrix Proteins; 0/matrix Gla protein; 81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Motor proficiency of 6- to 9-year-old children with speech and language problems.
Next Document:  Not a simple fat-soluble vitamin: changes in serum 25-(OH)D levels are predicted by adiposity and ad...